These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1151699)

  • 41. Improving the dissolution rate of poorly water soluble drug by solid dispersion and solid solution: pros and cons.
    Chokshi RJ; Zia H; Sandhu HK; Shah NH; Malick WA
    Drug Deliv; 2007 Jan; 14(1):33-45. PubMed ID: 17107929
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of pharmaceutical solubility Via NRTL-SAC and COSMO-SAC.
    Tung HH; Tabora J; Variankaval N; Bakken D; Chen CC
    J Pharm Sci; 2008 May; 97(5):1813-20. PubMed ID: 17786984
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
    Raw AS; Furness MS; Gill DS; Adams RC; Holcombe FO; Yu LX
    Adv Drug Deliv Rev; 2004 Feb; 56(3):397-414. PubMed ID: 14962589
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design.
    Vandecruys R; Peeters J; Verreck G; Brewster ME
    Int J Pharm; 2007 Sep; 342(1-2):168-75. PubMed ID: 17573214
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The solubility behaviour and thermodynamic relations of the three forms of Venlafaxine free base.
    van Eupen JT; Westheim R; Deij MA; Meekes H; Bennema P; Vlieg E
    Int J Pharm; 2009 Feb; 368(1-2):146-53. PubMed ID: 18996456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Pharmaceutical significance of amorphous materials].
    Antal I; Zelkó R
    Acta Pharm Hung; 2008; 78(3):121-33. PubMed ID: 18986089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Manufacturing Amorphous Solid Dispersions with a Tailored Amount of Crystallized API for Biopharmaceutical Testing.
    Theil F; Milsmann J; Anantharaman S; van Lishaut H
    Mol Pharm; 2018 May; 15(5):1870-1877. PubMed ID: 29648833
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of nicergoline polymorphs crystallized in several organic solvents.
    Malaj L; Censi R; Capsoni D; Pellegrino L; Bini M; Ferrari S; Gobetto R; Massarotti V; Di Martino P
    J Pharm Sci; 2011 Jul; 100(7):2610-22. PubMed ID: 21254066
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Crystal forms of the hydrogen oxalate salt of o-desmethylvenlafaxine.
    Dichiarante E; Curzi M; Giaffreda SL; Grepioni F; Maini L; Braga D
    J Pharm Pharmacol; 2015 Jun; 67(6):823-9. PubMed ID: 25644936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dissolution rates of high energy sulfathiazole--povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies.
    Simonelli AP; Mehta SC; Higuchi WI
    J Pharm Sci; 1976 Mar; 65(3):355-61. PubMed ID: 1263082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin-arginine.
    Lenz E; Jensen KT; Blaabjerg LI; Knop K; Grohganz H; Löbmann K; Rades T; Kleinebudde P
    Eur J Pharm Biopharm; 2015 Oct; 96():44-52. PubMed ID: 26197392
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Physicochemical basis of increased bioavailability of a poorly water-soluble drug following oral administration as organic solutions.
    Serajuddin AT; Sheen PC; Mufson D; Bernstein DF; Augustine MA
    J Pharm Sci; 1988 Apr; 77(4):325-9. PubMed ID: 3379591
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of manufacturing method for rapidly disintegrating oral tablets using the crystalline transition of amorphous sucrose.
    Sugimoto M; Narisawa S; Matsubara K; Yoshino H; Nakano M; Handa T
    Int J Pharm; 2006 Aug; 320(1-2):71-8. PubMed ID: 16750604
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Characterization of solvatomorphs of methotrexate using thermoanalytical and other techniques.
    Chadha R; Arora P; Kaur R; Saini A; Singla ML; Jain DS
    Acta Pharm; 2009 Sep; 59(3):245-57. PubMed ID: 19819822
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development of orodispersible polymer films with focus on the solid state characterization of crystalline loperamide.
    Woertz C; Kleinebudde P
    Eur J Pharm Biopharm; 2015 Aug; 94():52-63. PubMed ID: 25976316
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmaceutical development of an amorphous solid dispersion formulation of elacridar hydrochloride for proof-of-concept clinical studies.
    Sawicki E; Schellens JH; Beijnen JH; Nuijen B
    Drug Dev Ind Pharm; 2017 Apr; 43(4):584-594. PubMed ID: 28010129
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modeling the solubility of pharmaceuticals in pure solvents and solvent mixtures for drug process design.
    Ruether F; Sadowski G
    J Pharm Sci; 2009 Nov; 98(11):4205-15. PubMed ID: 19283772
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmaceutical sciences-1975: literature review of pharmaceutics I.
    Goodhart FW; Eichman ML
    J Pharm Sci; 1976 Jul; 65(7):935-62. PubMed ID: 784945
    [No Abstract]   [Full Text] [Related]  

  • 60. Soy polysaccharide as a novel superdisintegrant in sildenafil citrate sublingual tablets: preparation, characterization, and in vivo evaluation.
    Hosny KM; Mosli HA; Hassan AH
    Drug Des Devel Ther; 2015; 9():465-72. PubMed ID: 25624751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.